PDF(Pubmed)
Abstract：
Thyroid cancer has become more common in recent years all around the world. Many issues still need to be urgently addressed in the diagnosis, treatment, and prognosis of thyroid cancer. Liquid biopsy (mainly circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and circulating exosomes) may provide a novel and ideal approach to solve these issues, allows us to assess the features of diseases more comprehensively, and has a function in a variety of malignancies. Recently, liquid biopsy has been shown to be critical in thyroid cancer diagnosis, treatment, and prognosis in numerous previous studies. In this review, by testing CTCs, ctDNA, and exosomes, we focus on the possible clinical role of liquid biopsy in thyroid cancer, including diagnostic and prognostic biomarkers and response to therapy. We briefly review how liquid biopsy components have progressed in thyroid cancer by consulting the existing public information. We also discuss the clinical potential of liquid biopsy in thyroid cancer and provide a reference for liquid biopsy research. Liquid biopsy has the potential to be a useful tool in the early detection, monitoring, or prediction of response to therapies and prognosis in thyroid cancer, with promising clinical applications.
摘要：
近年来，甲状腺癌在世界各地变得越来越普遍。诊断中仍有许多问题亟待解决,治疗,甲状腺癌的预后。液体活检（主要是循环肿瘤DNA（ctDNA），循环肿瘤细胞（CTC），和循环外泌体)可能提供一种新颖而理想的方法来解决这些问题，使我们能够更全面地评估疾病的特征，并对多种恶性肿瘤有作用。最近,液体活检已被证明是甲状腺癌诊断的关键，治疗,和预后在许多以前的研究。在这次审查中,通过测试CTC，ctDNA,和外泌体，我们关注液体活检在甲状腺癌中可能的临床作用，包括诊断和预后生物标志物和对治疗的反应。通过查阅现有的公共信息，我们简要回顾了液体活检组件在甲状腺癌中的进展。我们还讨论了液体活检在甲状腺癌中的临床潜力，为液体活检研究提供参考。液体活检有可能成为早期检测的有用工具，监测,或预测甲状腺癌对治疗的反应和预后，有希望的临床应用。
